top of page

Apsis Consulting Group

Home

Who We Serve

About
Contact

Tel. 475-237-7994

54 State Street, STE 804 #8573

Albany, New York 12207

The $23M Lesson: Why MedTech VCs Need Regulatory Due Diligence

  • Jan 13
  • 3 min read

Owlet's Smart Sock seemed like a winning product: Parents loved it. Revenue was growing. Then the FDA issued a warning letter calling the device adulterated and misbranded.


The result: A $23.2 million contra-revenue adjustment. Sales halted. Retailer suspensions. Public returns. And a two year delay before sales could begin.


The biggest This was entirely predictable—and preventable.


The Pattern Repeating Across Your Portfolio


While VCs deployed $11.3 billion into MedTech in 2025, a predictable pattern is destroying value:


  • Owlet: $23.2M hit from unauthorized market enforcement + 2 year delay

  • 23andMe: Two-year US market withdrawal for health-related tests


These aren't edge cases. The regulatory debt accumulating in MedTech portfolios has driven countless promising startups to zero.



The Myths That Creates Regulatory Uncertainty


MYTH 1: "We'll use disclaimers to stay wellness."

The FDA doesn't read your terms and conditions, they look at the target's intended use and the marketing language on their website. Owlet had disclaimers. 23andMe had disclaimers. Both received warning letters anyway because the FDA evaluates objective intent: functionality, marketing context, design features.


MYTH 2: "We'll figure out FDA after launch."

Launch is the violation if the product as a medical intent or its technology can pose a risk to users. Selling before clearance creates unauthorized market exposure that triggers enforcement. This isn't "moving fast" or "being scrappy" its generating evidence of intent that the FDA will cite in their warning letter.


MYTH 3: "Our pilot data will support the submission."

Data collected without design controls under GCP is almost never submission-ready. The FDA doesn't just look at the study, they care that you followed 21 CFR 820 while designing the device and collecting the evidence and that the endpoints match the claims. Without proper controls, that pilot your target spent $500K on becomes a proof-of-concept that'll need to be redone. The second study costs more because now you're fixing the quality system simultaneously.




What $17K Prevents vs. What $1M Fixes


On a $3.5M seed round, regulatory diligence costs 0.5–1.5% of the check size: $17k–$50k. This is cheap insurance to protect your investment. What are the goals of Regulatory Diligence?


That investment answers (at a minimum) five questions:


  1. Claims & Intended Use: What does the product actually do? (Not what the pitch deck says—what the FDA will conclude based on functionality)

  2. Pathway Prediction: 510(k), De Novo, or PMA? Does a predicate exist with matching indications? What are the risks associated with each pathway?

  3. Evidence Architecture: Does the evidence plan align with claims? Or are they collecting "pilot data" without design controls that will be unusable for submission?

  4. QMS Maturity: Are design controls in place and operating? Can they survive an FDA inspection?

  5. Market Behavior: Where is it being sold? What do users see? Are disclaimers fighting against objective medical intent?



Skip this early, and the late-stage costs compound:

  • Unusable pilot data → Complete study redo: $500K–$2M

  • Missing predicate logic → Forced pathway reset: 12–18 month delay

  • Unauthorized market enforcement → $23.2M adjustment (see: Owlet)



The Diligence Spine


Every regulatory assessment starts with the same question: Does the evidence match the claim?


If the answer is no—or "tbd"—you're funding regulatory uncertainty that grows with every dollar invested.


The spine looks like this:

Claims → Pathway → Evidence → QMS → Allowed Marketing

Break any link, and everything downstream collapses.



Why This Matters Now


Deal flow has concentrated on later-stage companies (65% of MedTech funding in 2025). Investors are prioritizing de-risked assets with proven clinical data.


But here's the trap: most regulatory risk is created at the seed stage and only becomes visible at Series A.


By the time you're writing a $50M Series B check, the regulatory decisions are made. The claims are locked. The evidence plan is executing. The QMS either exists or it doesn't. The mistakes are made and aren't easily corrected without breaking investor promises.



The Three Things That Protect Capital


If you fund MedTech companies and remember nothing else:


1. Claims come first.They dictate pathway, evidence burden, and what you're allowed to sell. Get this wrong, everything downstream collapses.


2. "Wellness" is not a shield.FDA evaluates objective intent. Disclaimers don't outweigh what the product actually does.


3. Diligence is leverage.Spending 0.5–2% of check size early prevents regulatory debt—forced rework, recalls, and enforcement actions that destroy 10–50x that value later.



What Happens Next


The founders building the next generation of MedTech will either:

  • Lock claim boundaries early, build evidence that maps to those claims, and reach market with defendable positioning, or

  • Drift claims, generate unusable data, face enforcement, and burn capital on preventable rework


Your diligence budget determines which path your portfolio takes.


Ery Anguiano is the founder of APSIS Consulting Group, specializing in regulatory strategy for MedTech startups and investors. With 16+ years of FDA pathway expertise, he helps VCs spot regulatory uncertainty before it destroys value.


Download the Comprehensive Due Diligence Rubric: 





 
 
 

Comments

bottom of page